Growth recovery on the cards for Sanofi

The company's diabetic portfolio, line-extensions, and new products should help drive earnings

The year 2016 may have not been good for Sanofi India, and March 2017 quarter numbers did not impress either. But, the company’s fortunes are seen changing for the better.
 
The company follows a January-December financial year. While 2016 performance was impacted because of the new drug pricing policy and demonetisation, the March 2017 quarter numbers were weighed down by prolonged effect of the note ban and lower exports revenue. Sanofi said lower export volumes and rupee appreciation versus the euro had an adverse impact on its sales and profitability for the quarter.
 
These events have weighed on